Simposi


#Neurologytour "Innovation in neurological disorders therapies and neuroprotection" Thursday, October 26th 11.00-13.00
Acetylsalicylic acid, 120 years later Wednesday, October 25th 14.30-16.30
Advanced Therapies And Medical Devices Combination With Innovative Therapies Friday, October 27th 16.00-18.00
Advances in Multiple Sclerosis Thursday, October 26th 9.30-10.30
Appropriate use of opiates and risk of abuse liability Friday, October 27th 10.30-11.30
Cardiovascular Risk Prevention And The Chronic Patient Saturday, October 28th 10.30-12.00
Clinical and experimental aspects of novel antidiabetic therapies. From the gut and the kidney towards the cardiovascular system: the last ten years of the antidiabetic drugs. Thursday, October 26th 14.00-16.00
Clinical Perspectives of Neutraceuticals Thursday, October 26th 14.00-16.00
Clinical Pharmacology Of Cardio-Oncology Friday, October 27th 10.30-12.30
Curent topics and perspectives of precision therapy in oncology Thursday, October 26th 11.00-13.00
Effectiveness and Safety of Direct Oral Anticoagulants in Clinical Practice: Comparison of viewpoints Thursday, October 26th 17.00-18.00
Efficacy, Safety and effectiveness of isglt 2 (Sodium Glucose Co-tra nsporter Type 2 Inhibitor ): current and future role Friday, October 27th 11.30-12.30
Emerging epigenetic strategies in pharmacological therapy Thursday, October 26th 17.00-19.00
Environmental Enrichment And Brain Repair: The Therapeutic Effects O Cognitive Training In Neurological Diseases Friday, October 27th 8.30-9.30
Evolution Of The Therapeutic Approach To The Hiv Infection: Not Only “Viral Load” Friday, October 27th 10.30-11.30
From Big Data To Smart Data: Aims, Tools And Knowledge In The Real World Evidence Friday, October 27th 9.30 - 11.30
From Psychological Stress To Neurodegeneration: Novel Pharmacological Targets And Neuroprotective Approaches Friday, October 27th 8.30-10.30
From Urate Depositions to CV risk: The Role of the Xanthine-Oxidase Modulation Thursday, October 26th 14.00-15.00
Heart Failure : different approaches to the same problem Thursday, October 26th 8.30-10.30
Hepatitis C Therapy: Pharmacokinetics, Pharmacodynamics And Clinical Outcomes Friday, October 27th 15.30-16.30
Innovation of Mechanism of Action in Oncology Thursday, October 26th 15.00-16.00
Neurofunctional and metabolic alterations induced by maladaptive eating and stress: serching for novel pharmacological targets Wednesday, October 25th 14.30-16.30
Neuroprotection And Neuroenhancement: Lessons Learned From Ocular Disorders Friday, October 27th 14.30-16.00
New approaches to the inflamation pharmacology Thursday, October 26th 10.30-12.30
New Directions in Orphan Drugs for Rare Diseases: From Clinical Trials to Regulatory Paths Friday, October 27th 8.30-11.00
New Insights On Osteoporotic Drugs And Future Therapeutic Prospectives Saturday, October 28th 11.00-12.00
Novel Biological And Pharmacological Aspects In The Brain Tumors Friday, October 27th 8.30-9.30
Nutraceutical compounds: current and future perspectives Thursday, October 26th 11.00-13.00
Old And New Fields For Ion Channel Pharmacology: Still Surfing On The Crest Of A Wave Saturday, October 28th 10.30-12.00
On the bright and the dark side of amyloid beta: loking over Alzheimer’s diseas Thursday, October 26th 14.00-16.00
Patient Centricity Friday, October 27th 11.30-12.30
Pediatric pharmacology and the new EUROPEAN UNION (EU) Clinical trial regulation : perspectives and oportunities Wednesday, October 25th 14.30-16.30
Pharmacological control of tumor necrosis factor (TNF) in immunomediated inflammatory diseases (IMID): the value of Adalimumab Thursday, October 26th 14.00-15.00
Pharmacological Modulation Of Novel Molecular Systems In The Management Of Patients With Complex Pathologies Friday, October 27th 14.30-15.30
Pharmacological Strategies Defending The Heart From Fat Attack: A New Role For Direct-Acting Oral Anticoagulants Doac? - The Epicardial Adipose Tissue (Epa), A Sick (Visceral) Fat Embracing The Heart Saturday, October 28th 9.00-10.30
Phenotyping chronic obstructive pulmonary disease (COPD): pharmacological and toxicological implications Thursday, October 26th 8.30-10.30
Precision Medicine And Pharmacological Treatment Of Psychiatric Disorders Friday, October 27th 14.30-16.00
Psychiatric vulnerability of the developing brain: suggestions from animal models and critical time windows for pharmacological intervention Thursday, October 26th 17.00-19.00
Rare Diseases Therapy: From Clinical Needs to Therapeutic Solutions Friday, October 27th 11.00-12.00
Stress-induced psychopathologies: molecular markers of vulnerability and novel pharmacological targets Thursday, October 26th 8.30-10.30
Study, Development and Rationale Use of Immunopharmacological Agents Thursday, October 26th 17.00-18.30
Th2 Pathway In Immunological Diseases: New Frontiers For Treatment Of Atopic Disease Friday, October 27th 14.30-16.00
The clinical evolution of pharmacology Thursday, October 26th 17.00-19.00
The Endocannabinoid System And Autism Spectrum Disorders Friday, October 27th 16.30-18.30
The Future of Pharmacovigilance and the role of Risk Comunication Thursday, October 26th 8.30-10.30
The Pharmacologist And The Microbiota Challenge Friday, October 27th 10.30-12.30
The Purinergic System: A New Promising Target For Human Diseases Saturday, October 28th 9.00-11.00
Translational Research Openings for the Cure of Amyotrophic Lateral Sclerosis (ALS) Friday, October 27th 16.00-18.00
Translational strategy for assessing new mechanisms for the development of innovative therapeutic approach in psychiatric disorders Thursday, October 26th 8.30-10.30
Type 2 Diabetes: Glycemic Control and Innovation Therapy Thursday, October 26th 12.30-13.00